Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 1.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,417,354 shares of the biopharmaceutical company’s stock after selling 19,677 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.11% of Gilead Sciences worth $103,821,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Altfest L J & Co. Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $210,000. Federated Hermes Inc. lifted its position in Gilead Sciences by 4.9% during the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after buying an additional 175,925 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Gilead Sciences by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after buying an additional 87,482 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in Gilead Sciences during the fourth quarter worth about $74,000. Finally, Eagle Asset Management Inc. lifted its position in Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock worth $25,724,000 after buying an additional 60,697 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 1.7 %

Shares of GILD traded down $1.12 during trading hours on Wednesday, reaching $63.15. The stock had a trading volume of 6,684,551 shares, compared to its average volume of 6,773,233. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The firm has a 50-day moving average of $65.79 and a 200 day moving average of $73.13. The company has a market cap of $78.68 billion, a P/E ratio of 175.42, a P/E/G ratio of 1.28 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILDGet Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.37 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.88%. Gilead Sciences’s dividend payout ratio is 855.56%.

Analyst Upgrades and Downgrades

GILD has been the subject of several research analyst reports. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Royal Bank of Canada restated a “sector perform” rating and set a $74.00 price objective on shares of Gilead Sciences in a research note on Friday, June 14th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Finally, UBS Group cut their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $83.69.

Read Our Latest Analysis on GILD

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.